ADMA Biologics Inc $ADMA Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC grew its position in ADMA Biologics Inc (NASDAQ:ADMA) by 8.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,320,251 shares of the biotechnology company’s stock after purchasing an additional 271,305 shares during the period. Allspring Global Investments Holdings LLC’s holdings in ADMA Biologics were worth $59,366,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC lifted its position in ADMA Biologics by 1,149.1% during the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 2,505 shares in the last quarter. GAMMA Investing LLC lifted its position in ADMA Biologics by 251.6% during the 1st quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 4,715 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in ADMA Biologics by 7.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 70,991 shares of the biotechnology company’s stock worth $1,408,000 after acquiring an additional 4,865 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in ADMA Biologics during the 1st quarter worth approximately $240,000. Finally, PFG Investments LLC lifted its position in ADMA Biologics by 0.6% during the 1st quarter. PFG Investments LLC now owns 222,809 shares of the biotechnology company’s stock worth $4,421,000 after acquiring an additional 1,301 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “buy (b-)” rating on shares of ADMA Biologics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $27.67.

ADMA Biologics Stock Performance

Shares of ADMA opened at $14.95 on Wednesday. The business’s 50 day moving average is $16.15 and its two-hundred day moving average is $18.47. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67. The firm has a market cap of $3.57 billion, a price-to-earnings ratio of 17.38 and a beta of 0.47. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The company had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same period in the prior year, the company posted $0.13 EPS. ADMA Biologics’s quarterly revenue was up 13.8% on a year-over-year basis. Analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.